Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

Antibiotic resistance is a pressing issue within the realm of global health, posing significant challenges, particularly in ...

The drug – called zosurabalpin – has been shown to be effective against carbapenem-resistant Acinetobacter baumannii ... reserved for patients with multidrug-resistant infections, so ...

Named Acinetobacter baumannii (A ... research collaboration to tackle the pressing issue of the spread of multidrug resistant bacteria, more so when there is scarcity of data from certain parts ...

The study, published last week in The Lancet Oncology, mined 4 years of microbiologic data and found that the proportion of ...

Class A enzymes include β-lactamases that are active against penicillins and cephalosporins as well as extended-spectrum β-lactamases that are also active against penicillins and cephalosporins ...

The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug ... such as Acinetobacter baumannii and ...

The clinical burden of carbapenem-resistant Acinetobacter baumannii has worsened across U.S. hospitals in recent years, according to a study published April 17 in BMC Infectious Diseases.

Even with more restrictive assumptions, the analysis still showed a substantial treatment gap, with only 14.2% of patients ...

A virulent strain of antibiotic-resistant ... of the spread of multidrug resistant bacteria, more so when there is scarcity of data from certain parts of the world." A. baumannii can cause ...

inhibiting the growth of several multidrug-resistant (MDR) pathogens and biofilm formation. By disrupting the cell envelope, saccharin was shown to re-sensitize carbapenem-resistant A. baumannii ...